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Pancreatic neuroendocrine tumours (pNET) account for 
approximately 30% of all gastro-entero-pancreatic neo-
plasms [1]. Most pNETs occur as sporadic tumours, but 
9% are components of hereditary syndromes [multiple 
endocrine neoplasia type 1, von Hippel-Lindau disease 
(VHL), von Recklinghausen disease]. Approximately 1% 
all pNETs are associated with VHL [1–3].
Somatostatin analogues (SSA) octreotide and lanreo-
tide are recommended as first-line systemic treatments 
in non-functional pNETs with low proliferation index 
and good somatostatin receptor (SSTR) expression, due 
to their widely proven antiproliferative effect and lim-
ited toxicity [1, 3, 5]. Despite their similar mechanism of 
action, sequential therapy of one followed by another in 
patients with disease progression could still be effective 
in disease stabilisation.
This paper shows the clinical challenges and dilem-
mas in the management of advanced pNET in a young 
patient with VHL syndrome.
In February 2015, a 16-year-old female patient with 
a several-month-long history of abdominal pains, di-
arrhoea, and weight loss was admitted to the hospital 
due to cholestasis and jaundice. Contrast-enhanced CT 
showed a pancreatic head tumour 86 × 76 × 77 mm, 
with liver penetration and infiltration of the mesenteric 
vessels, and portal and splenic veins Additionally, en-
larged paraaortic lymph nodes and liver metastases in 
segments V, VII, and IV were described. Pancreatoduo-
denectomy with cholecystectomy (Whipple procedure) 
accompanied by gastrointestinal anastomosis formation 
using the Traverso-Longmire method and resection of 
a metastatic liver lesion were performed.
Histopathological examination confirmed pNET 
G2 infiltrating small nerve trunks, blood vessels, the 
wall of the small intestine, and bile duct (Ki-67 5%, 
liver with lymph node metastases 2/7). Post-operative 
[99mTc]Tc-DOTA-TOC SPECT/CT identified pathological 
somatostatin receptor (SSTR) expression in a pancreatic 
head tumour (30 × 24 mm) and in liver metastasis (seg-
ment VII — 15 mm).
Genetic testing for the MEN1 gene was negative. 
Because of the patient’s young age and an aggressive 
tumour type, further genetic testing was conducted, 
finding an abnormality in the VHL gene. The analysis 
of the VHL gene mutation in parents and siblings was 
negative.
After obtaining approval from the National Health 
Fund (NHF), the adolescent patient was qualified for 
an off-label therapy with octreotide LAR every 4 weeks 
(starting with the dose of 20 mg and then 30 mg) causing 
stabilisation of the disease.
After 10 months of the therapy, in March 2016, 
a control [68Ga]Ga-DOTA-TATE PET/CT followed by 
magnetic resonance imaging (MRI) showed the disease 
progression (increase pNET to 41 × 26 mm and new 
liver metastases all having good SSTR expression). Due 
to disease progression and again after obtaining a posi-
tive opinion from the NHF, octreotide LAR was changed 
to lanreotide Autogel (120 mg s.c. every 4 weeks).
From May 2016 until now the therapy has been 
continued, with good tolerance and without clini-
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cally relevant adverse events. On the follow-up [68Ga]
Ga-DOTA-TATE PET/CTs (Fig.1) and MRI scans, no 
disease progression has been reported. Currently there 
are no other symptoms characteristic of VHL.
VHL is a hereditary autosomal dominant syndrome in 
which benign and malignant tumours develop in the 
central nervous system (CSN) and visceral organs. The 
disease incidence is 1/36,000 live births, and it results 
from mutations in the VHL tumour suppressor gene lo-
cated on chromosome 3. The most characteristic tumours 
in VHL are hemangioblastoma of the retina and CSN, 
clear cell renal carcinoma (RCC), pheochromocytoma, 
and tumour of the inner ear or pancreas. Hemangioblas-
tomas and RCCs are associated with high morbidity and 
mortality [2, 4]. Of all VHL patients, 10–17% develop 
pNET [1, 3]. pNET connected with VHL are generally 
non-functional (rarely cause symptomatic disease) and 
have metastatic potential, so they should be optimally 
operated before metastatic spread. Krauss et al. reported 
that significant risk factors of metastatic pNET potential 
are maximum tumour diameter ≥ 2.8 cm, tumour vol-
ume doubling time (≤ 24 months), and the mutation in 
exon 3 — especially of codon 161 and 167 [2, 4].
We present a very rare situation in which advanced, 
aggressive pNET is the first and only presentation of 
VHL syndrome. Additionally, the patient has a de novo 
mutation of the VHL gene (codon 161) and none of the 
other family members is affected by VHL syndrome. 
Management guidelines for aggressive VHL-pNETs 
are based on limited evidence, making this case more 
challenging. 
The situation of young patient seemed difficult to 
treatment. At diagnosis, radical resection was impos-
sible due to advance and dissemination of the disease, 
making systemic treatment necessary. The confirma-
tion of SSTR expression in the remnant tumour mass 
enabled off-label SSA therapy in the adolescent patient. 
After pNET progression a simple switch to another SSA 
resulted in long-lasting disease stabilization.
In summary, the combination of a surgery and se-
quential therapy with long-acting SSA gave a very prom-
ising 6 years of stabilisation of aggressive VHL-pNET.
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Figure 1. [68Ga]Ga-DOTA-TATE PET/CT — February 2021 — pathological SSTR expression in pancreatic head tumour and in liver 
metastases (segment VII/VIII and V)
